Autolomous and Cellular Origins Target Cell Therapy Scale-Up Challenges with Partnership
The integration of Autolomous’ autoloMATE system and Cellular Origins’ Constellation platforms aims to standardize and digitize cell therapy manufacturing within existing bioprocess infrastructure.
Biotech SaaS company, Autolomous, and UK-based biotech, Cellular Origins, have announced an integration of their respective platforms to combine automation with cell therapy manufacturing. The collaboration focuses on delivering a fully connected, end-to-end orchestration of cell therapy manufacturing to address the challenges of scalability and data fragmentation within the sector (1).
Cellular Origins’ Constellation is a configurable, mobile robotic platform for scalable cell therapy manufacturing. The system combines automation, sterile fluid handling, and a modular architecture to help developers scale from clinical to commercial production without redesigning their process. Additionally, the system is designed to integrate with existing bioprocessing technologies and support standardized, traceable manufacturing with less manual intervention and lower scale-up risk.
Complementing Constellation is Autolomous’ autoloMATE platform — a cloud-native digital layer that enables real-time data exchange across instruments, software systems and robotic platforms. The system is designed to maintain data integrity and intellectual property protection while providing end-to-end visibility across manufacturing and supply chain operations.
Initial integrations have already been demonstrated at the Cell and Gene Therapy Catapult’s Digital and Automation Testbeds through an Innovate UK-funded program, to provide early validation in a semi-commercial environment.
“Scientific ambition has never been the bottleneck in bringing innovative cell therapy to patients, but the delivery infrastructure has brought many challenges,” said Alexander Seyf, CEO of Autolomous, in a company press release (1). “Together with Cellular Origins, we enable fast and efficient scaling from research through to patient administration, ensuring standardisation, automation and digitization across the entire process.”
“Scaling cell therapy manufacturing is not just a question of employing automation; it requires a manufacturing system that can evolve with demand,” added Edwin Stone, CEO of Cellular Origins, in the press release (1). “Our collaboration with Autolomous – and joint work with the Cell and Gene Therapy Catapult – clearly demonstrates how robotic platforms and digital infrastructure can operate as one.”
Cell therapies hold significant promise for the future of medicine but remain notoriously difficult and costly to manufacture at scale. Partnerships like the one between Autolomous and Cellular Origins hint at how technology and software could shift manufacturing, turning today’s small-scale production into more adaptive, software-orchestrated systems that can automate and scale over time.
Reference
Cellular Origins. Autolomous and Cellular Origins Expand Platform Integration to Deliver End-to-End Cell Therapy Manufacturing Orchestration. Press Release, July 8, 2026.